Ferring continues to grow in Switzerland
Non classé
25 July 2016
The biopharmaceutical company plans to create 300 jobs by 2020 at its corporate headquarters in Saint-Prex. On the occasion of the 10th anniversary of its presence in Switzerland, Ferring Pharmaceuticals has announced its intention to create 300 additional jobs at its corporate headquarters in Saint-Prex, in the canton of Vaud. The company currently employs some […]
The biopharmaceutical company plans to create 300 jobs by 2020 at its corporate headquarters in Saint-Prex.
On the occasion of the 10th anniversary of its presence in Switzerland, Ferring Pharmaceuticals has announced its intention to create 300 additional jobs at its corporate headquarters in Saint-Prex, in the canton of Vaud. The company currently employs some 680 people in Saint-Prex and plans to have 1,000 employees by 2020. In addition to the company’s corporate headquarters, the Saint-Prex site houses a production facility where two of its flagship products are manufactured: Minirin, an antidiuretic hormone, and Pentasa, used for the treatment and long-term management of inflammatory bowel diseases. The production unit operates continuously.
According to Ferring president and CEO Michel Pettigrew, Switzerland remains a unique location for companies in spite of the abolition of the minimum exchange rate against the euro in January 2015: “We are extremely satisfied with our presence in the canton of Vaud, and we want to stay here. For us, the discontinuation of the minimum exchange rate was mainly an opportunity to improve our productivity”, he told Swiss newspaper Le Temps.
First founded in Sweden in 1950, the biopharmaceutical company is present in 56 countries and employs 6,700 people.
